RheinCell Therapeutics GmbH, a developer and manufacturer of human induced pluripotent stem cells (iPSCs) as starting materials for cell therapies, has received Good Manufacturing Practice (GMP) certification and Manufacturing Authorization.   The certificate and accompanying manufacturing permit — which were granted following inspection of RheinCell’s manufacturing facilities in September 2020 — confirm that the company’s site follows the GMP principles of the European Union for human med...